Goldman SachsGSTOP PICKNov 13, 2025Stock price when the opinion was issued
As of Jul 20, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
Global powerhouse in the financial space. Moving away from the consumer and more toward higher-margin asset management. Expected earnings growth of ~15%. Recovery in capital markets, investment banking volumes improving.
(Analysts’ price target is $814.59)Lower interest environment and more risk appetite out there. Potential policy tailwinds such as more deregulation and lower corporate taxes. Will see more share buybacks. Yield is 1.92%.